Whilst there has been a lot of discussion in the UK about an incoming Prime Minister and ‘Manchesterism’, it has certainly been the case that the busy bees have not been confined to that city.
Tony Jones, CEO, One Nucleus. Email: [email protected]
Topics in this article:
How One Nucleus delivers maximum support at minimum cost
Dates for your Diary
Looking ahead to 2027
It has Been a Busy Summer!As everyone returns to playing their particular role in helping push back the frontiers of biomedicine to create innovative medicines and technologies to improve patient outcomes, I am…
*Guest blog by Gavin Allsop, Commercial Director, Lab Thread. If you would like to submit a guest blog please email [email protected].
In September 2025, my consulting company was hired to find alpha testers for Lab Thread; a collaborative platform developed by Ryan Cawood and Deyan Sultov in response to an unmet need Ryan identified as CEO at OXGENE, namely the lack of easy to use and scalable solutions for the digital management of lab workflows.
Lab Thread’s goal was simple: build a platform so intuitive and effective that scientists choose it over pen and paper; and prefer it over…
The apparent tectonic shift in the global bio-innovation landscape has markedly accelerated, and 2025-26 is providing One Nucleus members with exciting opportunities and huge challenges like never before. Adapting to maintain the key role of convener, supporter, ally and compass for members navigating these changes has led One Nucleus to invest in developing a new toolbox to help our members.
by Tony Jones, CEO, One Nucleus - email: [email protected]
Topics in this article include:
Adapting in unfamiliar times
Navigating the…
*Guest blog by Eramol. If you would like to submit a guest blog please email [email protected] by David Cox, Site Director at EramolDavid has more than 20 years’ experience across engineering, technical functions, sterile manufacturing, technology transfer and pharmaceutical site operations.Connect with David on LinkedIn
Across a career spanning engineering, technical functions, sterile manufacturing, technology transfer and site operations, one pattern becomes difficult to ignore.
When a sterile fill-finish programme runs into trouble, the cause can often be traced to a much…
*Guest blog by Eramol. If you would like to submit a guest blog please email [email protected].
Early-phase clinical programmes often face a different set of challenges compared with late-stage or commercial manufacturing.
Drug substance may be scarce. The formulation may still be evolving. The clinical protocol may require flexibility. The sponsor may need enough finished product for first-in-human studies, dose escalation, cohort expansion, stability, analytical testing and contingency supply.
For this reason, sterile fill-finish strategy needs to be aligned with the realities of early…
*Guest blog by LimestoneGrey. If you would like to submit a guest blog please email [email protected].
Two loss-making biotechs each spend £100,000 on qualifying R&D in the same year. One receives £16,200 in cash. The other receives £26,970. Nothing they did in the lab was different. The difference? One ratio.
What Enhanced R&D Intensive Support is
ERIS is the relief reserved for loss-making SMEs whose qualifying R&D expenditure is at least 30% of their total relevant expenditure. It applies to accounting periods beginning on or after 1 April 2024 and pays up to 26.97p per £1 of…
Looking at patent filing data from the European Patent Office and international PCT system, the report reveals an interesting shift. While filing growth has slowed since the Metaverse boom, XR innovation remains strong and is increasingly focused on practical applications and commercial deployment across industries including healthcare, telecoms, automotive, aviation and entertainment.
Some of the key findings include:
XR innovation remains at historically high levels, despite slower growth
Smaller companies, start-ups and universities are playing an increasingly important role in driving…
From a first step into biotech cluster networking in 2000 my time involved with LBN and One Nucleus has provided me a source of many learnings about changes in myself, the members we support and the London biotech cluster generally.
Tony Jones, CEO, One Nucleus
Email: [email protected]
Topics in this article include:
My membership group and London biotech timeline
Early days of LBN
One Nucleus and the London-Cambridge biotech axis
London’s deal making growth
Event evolution
Lessons I have learned
Prompted to reflect
Philippa Clark’s recent blog entitled “What One Year at One…
The future of biotech fundraising may not belong to companies that pitch to the most investors. It will more likely belong to those that understand which investors are most likely to become long-term partners and how to navigate to them efficiently. In fundraising, as in medicine, precision is beating trial and error.
Tony Jones, CEO, One Nucleus, Email: [email protected]
Topics in this article include:
Sector sentiment update
Investing in precision
Spray & pray vs targeted fundraising
Leveraging AI and technology
Balancing cost…
*Guest blog by Lab Thread. If you would like to submit a guest blog please email [email protected].
Following the first commercial approvals in 2017, the chimeric antigen receptor (CAR) T-cell therapy market has expanded rapidly thanks to the significant impact these treatments have had on patient outcomes in hematologic cancers, and is projected to keep growing as CAR T-cell therapies are administered earlier in the patient’s treatment journey, and target indications expand from oncology into autoimmune conditions.
Reprogramming a patient’s T-cells in vivo is a promising approach to…